IMC Chicago’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.8M | Sell |
142,300
-21,100
| -13% | -$2.95M | 0.01% | 870 |
|
|
2025
Q4 | $20.1M | Sell |
163,400
-40,200
| -20% | -$4.89M | 0.01% | 850 |
|
|
2025
Q3 | $22.6M | Sell |
203,600
-27,900
| -12% | -$3.17M | 0.01% | 738 |
|
|
2025
Q2 | $25.7M | Buy |
231,500
+6,600
| +3% | +$702K | 0.01% | 596 |
|
|
2025
Q1 | $25.2M | Sell |
224,900
-14,700
| -6% | -$1.52M | 0.01% | 490 |
|
|
2024
Q4 | $22.1M | Buy |
239,600
+74,000
| +45% | +$6.66M | 0.01% | 573 |
|
|
2024
Q3 | $13.9M | Sell |
165,600
-48,800
| -23% | -$3.72M | 0.01% | 694 |
|
|
2024
Q2 | $14.7M | Buy |
214,400
+17,800
| +9% | +$1.19M | 0.01% | 636 |
|
|
2024
Q1 | $14.4M | Sell |
196,600
-59,400
| -23% | -$4.57M | 0.01% | 574 |
|
|
2023
Q4 | $20.7M | Buy |
256,000
+17,500
| +7% | +$1.36M | 0.01% | 450 |
|
|
2023
Q3 | $17.9M | Buy |
238,500
+5,100
| +2% | +$392K | 0.02% | 405 |
|
|
2023
Q2 | $18M | Sell |
233,400
-157,200
| -40% | -$12.5M | 0.02% | 395 |
|
|
2023
Q1 | $32.4M | Buy |
390,600
+26,600
| +7% | +$2.2M | 0.04% | 241 |
|
|
2022
Q4 | $31.2M | Buy |
364,000
+247,400
| +212% | +$19.6M | 0.05% | 226 |
|
|
2022
Q3 | $7.19M | Sell |
116,600
-59,700
| -34% | -$3.76M | 0.01% | 497 |
|
|
2022
Q2 | $10.9M | Sell |
176,300
-69,700
| -28% | -$4.32M | 0.02% | 417 |
|
|
2022
Q1 | $14.6M | Buy |
246,000
+11,600
| +5% | +$742K | 0.01% | 401 |
|
|
2021
Q4 | $17M | Buy |
234,400
+67,800
| +41% | +$4.67M | 0.01% | 393 |
|
|
2021
Q3 | $11.6M | Sell |
166,600
-5,500
| -3% | -$386K | 0.01% | 463 |
|
|
2021
Q2 | $11.9M | Sell |
172,100
-109,000
| -39% | -$7.28M | 0.01% | 423 |
|
|
2021
Q1 | $18.2M | Buy |
281,100
+36,200
| +15% | +$2.33M | 0.03% | 316 |
|
|
2020
Q4 | $14.3M | Sell |
244,900
-68,500
| -22% | -$4.13M | 0.02% | 339 |
|
|
2020
Q3 | $19.8M | Sell |
313,400
-85,200
| -21% | -$5.91M | 0.03% | 209 |
|
|
2020
Q2 | $30.7M | Sell |
398,600
-149,500
| -27% | -$11.5M | 0.06% | 115 |
|
|
2020
Q1 | $41M | Buy |
548,100
+408,900
| +294% | +$28.3M | 0.09% | 70 |
|
|
2019
Q4 | $9.04M | Buy |
139,200
+65,300
| +88% | +$4.25M | 0.02% | 234 |
|
|
2019
Q3 | $4.68M | Sell |
73,900
-10,400
| -12% | -$680K | 0.01% | 295 |
|
|
2019
Q2 | $5.7M | Buy |
84,300
+17,200
| +26% | +$1.13M | 0.02% | 257 |
|
|
2019
Q1 | $4.36M | Sell |
67,100
-7,600
| -10% | -$505K | 0.02% | 259 |
|
|
2018
Q4 | $4.67M | Buy |
+74,700
| New | +$5.22M | 0.01% | 216 |
|
Other funds holding GILD
VCM
VPM
IMC Chicago's GILD Position: Q4 2025 in Review
IMC Chicago sold out of Gilead Sciences (GILD) in Q4 2025, closing a stake of 43,865 shares — an estimated $5.33M sold.
IMC Chicago first reported a position in GILD in Q4 2019 and held it in 12 quarters. The position peaked at $21.5M in Q4 2022. 2,215 funds tracked by Wall St. Rank hold GILD as of Q4 2025.
- IMC Chicago reported no remaining Gilead Sciences position as of Q4 2025 after selling out during the quarter.
- IMC Chicago sold 43,865 Gilead Sciences shares in Q4 2025, an estimated $5.33M.
- IMC Chicago first reported a position in Gilead Sciences in Q4 2019 and held it in 12 quarters.
- IMC Chicago's Gilead Sciences position peaked at $21.5M in Q4 2022.
- 2,215 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.
Based on IMC Chicago's 13F filing for Q4 2025, filed 29 Jan 2026.